Krystal Biotech

Krystal Biotech is a commercial-stage genetic medicine company that develops redosable topical and inhaled gene therapies for rare genetic diseases. The company manufactures Vyjuvek, the first FDA-approved redosable topical gene therapy for dystrophic epidermolysis bullosa, which delivers functional human collagen genes directly into wounded skin via a modified herpes simplex virus vector. Through its engineered viral delivery platform, Krystal Biotech expands non-invasive gene therapy into dermatology and pulmonology.